RetractedArticleBritish journal of haematology2013
The Bruton tyrosine kinase (BTK) inhibitor PCI-32765 synergistically increases proteasome inhibitor activity in diffuse large-B cell lymphoma (DLBCL) and mantle cell lymphoma (MCL) cells sensitive or resistant to bortezomib.
Girija Dasmahapatra et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
41 papers cite it
this papertrialcites it